FDA GUIDELINES FOR ADVERTISING COPYWRITERS At the end of this module, you will be able to recall FDA regulations related to pharmaceutical advertising.

Slides:



Advertisements
Similar presentations
FDA Public Hearing Promotion FDA Public Hearing Promotion of FDA-Regulated Medical Products Using the Internet November 12, 2009 Testimony of Interactive.
Advertisements

An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Preparing Print Ad Copy. Copy & It’s Objectives Text of a print advertisement that provides readers with information Text of a print advertisement that.
@ PMCQ October 14, Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.
Internal Audit A mostly friendly watchdog. Internal Audit is not an optional function. HEFCE requires that “each HEI must have an effective Internal Audit.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
International Seminar on Drug Advertising Canadian Experience Brazilian Health Surveillance Agency and Pan American Health Organization Brasilia, Brazil.
RAC Study Group Chapter 16
Pharmaceutical Development and Regulation Name brands, generics and the FDA.
What SMS means for an Operator’s relationship with the CAA
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs Adam Atherly and Paul H. Rubin Emory University.
 I can analyze information contained on a food label.
Copyright © 2009 by The McGraw-Hill Companies, Inc. All Rights Reserved. McGraw-Hill Chapter 5 Personal Health Records Electronic Health Records for Allied.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Stages of drug development
© 2009 Hogan & Hartson LLP. All rights reserved. Meredith Manning Partner May 20, 2009 FDA’s Internet Ad Warnings: Implications for Social Media National.
4 Chapter Business Ethics and Social Responsibility pp
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
11 March, 2010 Paris. 2 Life stages Danone brings health trough food at all life stages Maintain.
House Ad Project: Developing an Ad Campaign. Using the “House Ad” as a project I suggest the “House Ad” exercise as a possible project. It is most effective.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,
Modern Medicine vs. Holistic alternatives By Erika Hummel.
ADVERTISING- TO TARGET AUDIENCES. COPYRIGHT © TEXAS EDUCATION AGENCY, ALL RIGHTS RESERVED. 2 “Copyright and Terms of Service Copyright © Texas Education.
National Survey on Consumer Reaction to DTC Advertising of Prescription Medicines: Comments from DDMAC Kathryn J. Aikin, Ph.D. Division of Drug Marketing,
Managing Regulatory Changes June 24, Regulatory Change Management Critical Component of successful overall regulatory compliance risk management.
1 PhRMA Guiding Principles - DTC About Prescription Medicines.
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
THE FDA REGULATORY AND COMPLIANCE SYMPOSIUM Managing Risks – From Pipeline to Patient Presented by: Steven A. Johnson, Esq., Vice President and Assistant.
Regulatory & Public Health Implications of DTCA Economists Conference Louis A. Morris, Ph.D. April 29, 2003.
Data, Security and Human Subjects Research Deborah Barnard, MS.
How to Apply FDA Rules to the Emerging Social Media Environment National Pharma Audio Conference May 20, 2009.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
COMPARATIVE ANALYSIS OF SELECTED ESSENTIAL DRUG LISTS AZIZ JAFAROV/RICHARD LAING.
2 “The label is the most important product that a company’s research arm produces…” Essence of Licensure Conveys the Use of the Product Describes Efficacy.
FDA Regulatory and Compliance Symposium
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
CHAPTER 24 Advertising Permission granted to reproduce for educational use only.© Goodheart-Willcox Co., Inc. ADVERTISING CAMPAIGNS Section 24.1.
GUIDED ANALYSIS OF ADVERTISING COPYWRITING. LOOK AT THE CYMBALTA AD 
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
FDA Regulation of Pharmaceutical Marketing Tom Casola Executive Director Commercial Operations Merck & Co., Inc.
Government Regulatory Agencies and Impact on Consumer Choices Presentation.
General exam advice Do not write too much on ‘give’, ‘outline’, ‘identify’ or ‘state’ questions as you WILL run out of time. E.g. a three mark question.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Developing, Pilot Testing & Evaluating RiskMAP Interventions Annette Stemhagen, DrPH, FISPE Vice President UBC Epidemiology & Risk Management The FDA Regulatory.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
GCP (GOOD CLINICAL PRACTISE)
PowerPoint & Evaluating Resources PowerPoint & Evaluating Resources Mike Spindler & Emma Purnell.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 3 Drug Regulation, Development, Names, and Information.
1 Meredith Rosenthal, Ph.D. May 10, 2007 Direct-to-Consumer Advertising of Prescription Drugs.
Prescription Drug Advertising
Marketing Drugs to Healthy Women with Certain Risk Factors: What might the FDA do to prevent doing more harm than good? APHA November 2007 Judy Norsigian.
Unit 3 General exam advice
Advertising to Target Audiences
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
9. Introduction to signal detection
Classification of total cholesterol levels
Implementation Considerations
Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P
Pharmaceutical Industry & Consumers
What can we learn from careful reading of an image?
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Generic vs Name Brand Drugs
CREATING EFFECTIVE ADS
Compliance in the New Environment
Presentation transcript:

FDA GUIDELINES FOR ADVERTISING COPYWRITERS

At the end of this module, you will be able to recall FDA regulations related to pharmaceutical advertising with 100% accuracy MODULE OBJECTIVE

 Pharmaceutical companies spend millions of dollars on drug advertising  When copy is flagged for lack of regulatory compliance, it causes delays and increases cost  Multiple rounds of regulatory review by clients  Errors/misleading claims increase regulatory scrutiny and mistrust with agency  Client ultimately unhappy with agency and increased likelihood of relationship problems  If an error/misleading claim slips through review, the FDA can mandate corrective advertising (at clients’ expense) and seek punitive actions against client, agency and responsible personnel WHY SHOULD I CARE?

 Be accurate  Balance the risk and benefit information  Be consistent with the prescribing information (PI) approved by FDA  Only include information that is supported by substantial evidence or substantial clinical experience PRESCRIPTION DRUG ADVERTISING MUST

 A product claim ad names a drug, the disease/condition it treats, and presents both its benefits and risks.  A reminder ad gives the drug's name but not the drug's use nor its benefits and risks  There is a 3 rd type of drug ad: a help-seeking ad  Describes a disease or condition but does not recommend or suggest specific drugs A PRODUCT CLAIM AD VS A REMINDER AD

 There are several key elements to know when it comes to writing your copy:  Fair Balance/Important Safety Information (ISI)  Substantial Information  Claim  Benefit  Brief Summary  Risks/Side Effects KEY WRITING ELEMENTS

 In product claim advertising, fair balance refers to the presentation of “accurate and fair assessment of both the benefits and the risks of a drug”  The content/presentation of a drug's risks must be similar to the content/presentation of its benefits  This does not mean that equal space must be given to risks and benefits in print ads, or equal time to risks and benefits in broadcast ads  The amount of time or space needed to present risk information will depend on the drug's risks and the way that both the benefits and risks are presented  The risk information is often called the important safety information or ISI FAIR BALANCE

 Substantial evidence is the data that support claims  Before FDA approval, drug companies must complete studies to show the drug does what they say it does  They also required to support advertising claims about the drug  A drug must be supported by at least two studies to support claims SUBSTANTIAL EVIDENCE

 A claim says something about the advertised drug or what it does.  Claims usually relate to benefits  Claims can be made directly by stating, for example, "Brand X treats heartburn”  Claims also can be made indirectly by the use of pictures or other graphics.  E.g.: an Ad featuring a playground full of children may suggest a claim that the advertised drug treats children  Ads for prescription drugs can only make claims that are consistent with the drug's "prescribing information”  The truthfulness of claims must be supported by "substantial evidence" or substantial clinical experience CLAIM

 A benefit is a positive result(s) provided by a drug  E.g., the benefit of a cholesterol drug is that it lowers the levels of bad cholesterol (low-density lipoprotein, or LDL, cholesterol)  Benefits can only be advertised if they are related to the FDA- approved use  Advertised benefits must be supported by "substantial evidence” or substantial clinical experience BENEFIT

 Here is a link to the FDA website for correct and incorrect advertisements for product claim ads, reminder ads, and help- seeking ads iptionDrugAdvertising/ucm htm EXAMPLES

 criptionDrugAdvertising/UCM htm RESOURCES

You should now know key writing elements in regards to FDA regulations that you can apply when developing copy CONCLUSION